Proactive Investors - Run By Investors For Investors

AstraZeneca in cancer drug setback

The phase III trial involved patients with very late stage lung cancer where the disease had spread to other organs - in other words, the group was hard to treat
x-ray of a lung
It should be noted that Imfinzi is approved in more than 40 countries for patients with inoperable stage III lung cancer

AstraZeneca PLC (LON:AZN) said its drug Imfinzi was no better than chemotherapy in treating patients with non-small cell lung cancer which has spread to other organs.

The medication was used on its own and in combination with tremelimumab, an antibody treatment, in patients with stage-IV cancer.

READ: AstraZeneca sells off US rights to children’s lung disease treatment for up to US$2bn

The phase III clinical trial showed there was no statistical advantage to using the new drug.

 "We are encouraged to see that Imfinzi monotherapy activity is in-line with that of the anti-PD-1 class in previously-untreated patients with Stage IV non-small cell lung cancer; however, we are disappointed that these results missed statistical significance,” said AZ chief medical officer Sean Bohen.

“We remain confident in Imfinzi as the cornerstone of our IO [immuno-oncology] programme and continue to evaluate its potential in ongoing non-small cell lung cancer trials, including Imfinzi and Imfinzi plus tremelimumab in combination with chemotherapy."

It should be noted that Imfinzi is approved in more than 40 countries for patients with inoperable stage III lung cancer.

The latest trial was part of a batch of studies to assess just which forms of the disease the new drug is capable of treating.

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use